



MOLECULAR AND GENETIC FEATURES OF COAGULATION DISORDERS IN PATIENT WITH GOUT

Akramova Nigora Turdikulovna

1 st year PhD student at Tashkent medical academy. Tel: +998977234367;
email:akramovanigoraturdikulovna@gmail.com

DS, Professor Nabiyeva Dildora Abdumalikovna

Head of the faculty and hospital treatment, occupational diseases N1 department at Tashkent medical academy

Aditya Kush

1 st year medical student at Tashkent medical academy, international department. Tel: +998903460980 email:
dradityakush@gmail.com

Ibragimova Difuza Narzikulovna

Samarkand State Medical Institute. Tel: +998979111612

Akramov Iskandar Rahmonkulovich

Tashkent medical academy. Tel: +998976455522

Article history:

Received: April 4th 2023
Accepted: May 6th 2023
Published: June 6th 2023

Abstract:

Gout is a rheumatic disease characterized by hyperuricemia. It causes recurrent attacks of inflammation, pain, disability, and discomfort due to the accumulation of urate crystals in the joints, caused by overproduction or underexcretion of uric acid. Recent studies have shown that gout patients are prone to cardiovascular disease, including coagulation disorders like PE and DVT. The paper aims to summarize the possible link between gout and coagulation disorders by studying the molecular and genetic features of gout patients [1,2].

Keywords: Molecular, Genetic, Gout, Coagulation, Thrombosis, Uric acid,

Gout is a common form of arthritis that affects millions of people around the world. It is caused by the accumulation of uric acid crystals in the joints, leading to inflammation and pain. Gout is associated with a number of risk factors for **cardiovascular disease** including hypertension [1], obesity [2], a high alcohol intake [3], hyperlipidemia [4], hyperpre-betaipoproteinemia [5,6].

While gout primarily affects the joints, it has been found that patients with gout are at an increased risk of developing coagulation disorders [10]. In this article, we will examine the relationship between gout and coagulation disorders and what steps can be taken to mitigate their impact.

Coagulation disorders are a group of conditions that affect the body's ability to form a blood clot. Patients with gout are at an increased risk of developing coagulation disorders due to elevated levels of uric acid in the blood. Studies have shown that elevated uric acid levels can lead to increased platelet activation and fibrinogen production, two key components of the blood clotting process [7, 8, 9].

One of the most common coagulation disorders associated with gout is deep vein thrombosis (DVT). DVT occurs when a blood clot forms in the deep veins, typically in the legs [13]. The risk of developing DVT is higher in patients with gout due to the increased platelet activation and fibrinogen production mentioned earlier. In addition, gout inflammation can cause

damage to the blood vessels, further increasing the risk of DVT [13].

Another coagulation disorder that has been linked to gout is pulmonary embolism (PE) [13]. PE occurs when a blood clot travels from the legs to the lungs, potentially causing life-threatening complications. Studies have shown that patients with gout are at an increased risk of developing PE, likely due to the increased platelet activation and fibrinogen production associated with hyperuricemia [8, 9, 13].

While the relationship between gout and coagulation disorders is concerning, there are steps patients and healthcare providers can take to mitigate their impact. One of the most important steps is to manage the underlying gout. This typically involves medication and lifestyle changes to control uric acid levels and prevent flare-ups of gout inflammation. In addition, individuals with gout can take steps to improve their overall cardiovascular health. This includes regular exercise, a healthy diet, and avoiding smoking and excessive alcohol consumption.

For patients with gout who have already developed a coagulation disorder, treatment typically involves medications to thin the blood and prevent the formation of blood clots. Depending on the severity of the coagulation disorder, surgery or other procedures may be necessary.

Thus, patients with gout are at an increased risk of developing coagulation disorders such as DVT and PE



[13]. As mentioned above, elevated uric acid levels can lead to increased platelet activation and fibrinogen production, which can increase the risk of blood clots [7, 9]. However, with proper management of gout and lifestyle changes to improve cardiovascular health, this risk can be minimized.

It is obviously, gout is a common form of arthritis that is caused by the buildup of uric acid crystals in the joints. It is a complex disease with both genetic and environmental factors contributing to its development. One area of research that has received increasing attention in recent years is the role of genetic polymorphisms in coagulation factors in patients with gout.

Coagulation factors are proteins that are involved in the blood clotting process. Genetic polymorphisms are variations in the DNA sequence that affect the function of these proteins. Several studies have investigated the association between genetic polymorphisms in coagulation factors and the risk of gout.

One of the most studied coagulation factors in relation to gout is Factor V Leiden (FVL) [14]. FVL is a genetic mutation that results in a resistance to the anticoagulant protein C. Studies have shown that individuals carrying the FVL mutation have an increased risk of developing gout. In addition, gout patients with the FVL mutation have been found to have more severe joint damage compared to those without the mutation [14].

Another coagulation factor that has been studied in relation to gout is Factor II (prothrombin). The prothrombin gene contains a genetic variant known as the G20210A mutation, which results in increased levels of prothrombin. Studies have suggested that carriers of this mutation have an increased risk of developing gout [13].

Other coagulation factors that have been studied in relation to gout include Factor XIII, Factor XII, and von Willebrand factor. Studies have suggested that genetic polymorphisms in these factors may also be associated with an increased risk of gout [13].

The exact mechanisms by which genetic polymorphisms in coagulation factors contribute to the development of gout are not well understood. However, it is thought that these polymorphisms may affect the inflammatory response in the joints, leading to increased uric acid crystal formation and deposition.

Thus, genetic polymorphisms in coagulation factors may play a role in the development of gout. Further research is needed to better understand the mechanisms underlying this association and to identify potential therapeutic targets. Clinicians should be aware of the potential association between coagulation factor genetic

polymorphisms and gout and consider genetic testing in patients with a family history of gout or those with severe joint damage.

The exact mechanisms underlying the development of coagulation disorders in patients with gout are not fully understood. However, several factors have been implicated in the pathogenesis of these disorders.

One of the most important factors is inflammation. Gout is a chronic inflammatory disease that is characterized by the deposition of uric acid crystals in joints and surrounding tissues. This leads to the activation of the immune system, which triggers the release of inflammatory mediators such as cytokines and chemokines. These mediators can activate the coagulation cascade and promote the formation of clots. Another factor is oxidative stress. Uric acid crystals can induce oxidative stress, which is characterized by the production of reactive oxygen species (ROS) and the depletion of antioxidants. ROS can activate platelets and promote the formation of clots, leading to coagulation disorders.

Furthermore, hyperuricemia, which is a hallmark feature of gout, has been linked to coagulation disorders. Hyperuricemia can lead to endothelial dysfunction, which is characterized by the impaired production of nitric oxide (NO) and increased expression of adhesion molecules [12]. This can promote the adhesion and aggregation of platelets, leading to the formation of clots [7,8].

Clinical manifestations of coagulation disorders in patients with gout

Coagulation disorders in patients with gout can manifest in a variety of ways, depending on the severity and type of the disorder. Some common clinical manifestations include:

- Easy bruising: Patients with coagulation disorders may develop bruises easily, even with minor trauma or pressure.
- Prolonged bleeding: Patients may experience prolonged bleeding after injuries or surgeries, and may require transfusions of blood products.
- Petechiae: These are small, pinpoint-sized red or purple spots that appear on the skin as a result of bleeding under the skin.
- Hematomas: These are collections of blood that form under the skin or in other tissues, and can cause pain and swelling.
- Deep vein thrombosis (DVT): This is a serious condition in which blood clots form in the deep veins, usually in the legs. DVT can cause pain, swelling, and redness in the affected area, and can lead to pulmonary embolism (PE) if the clot travels to the lungs.



- Pulmonary embolism (PE): This is a life-threatening condition in which a blood clot travels to the lungs and blocks blood flow. PE can cause chest pain, shortness of breath, and rapid heartbeat.

Treatment options for coagulation disorders in patients with gout

The treatment of coagulation disorders in patients with gout depends on the underlying cause of the disorder and the severity of the clinical manifestations.

Coagulation disorders in patients with gout can be caused by a variety of factors, including increased levels of uric acid, inflammation, and the use of certain medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine [11, 16]. These factors can disrupt the normal balance between procoagulant and anticoagulant factors, leading to an increased risk of thrombosis and other clotting disorders.

The treatment of coagulation disorders in patients with gout involves a multifaceted approach, including the use of medications to control inflammation and uric acid levels, as well as the use of anticoagulant therapy when necessary [16,17].

NSAIDs and colchicine are commonly used to manage acute gout attacks, but they can also increase the risk of bleeding and coagulation disorders [16, 17]. Therefore, it is important to use these medications with caution in patients with gout who have a history of bleeding disorders or who are taking anticoagulant therapy [16, 17]. In cases where NSAIDs and colchicine are contraindicated or not effective, corticosteroids can be used to manage acute gout attacks [15, 16, 17]. Corticosteroids are also effective in reducing inflammation and can be used in combination with other medications to manage coagulation disorders in patients with gout [15, 17].

Uric acid-lowering therapy is the cornerstone of long-term management of gout and can also help prevent coagulation disorders [11, 17]. Allopurinol and febuxostat are two commonly used uric acid-lowering medications that have been shown to reduce the risk of thrombosis and other clotting disorders in patients with gout [7, 8, 11]. These medications work by inhibiting the production of uric acid, which can help reduce inflammation and improve blood flow [8, 15].

In addition to uric acid-lowering therapy, anticoagulant therapy can also be used to manage coagulation disorders in patients with gout. Anticoagulant therapy is typically used in patients with a high risk of thrombosis or other clotting disorders, such as those with a history of deep vein thrombosis or pulmonary embolism [13]. The most commonly used anticoagulant medications are warfarin, heparin, and direct oral anticoagulants (DOACs) such as apixaban, dabigatran, and rivaroxaban

[15]. The choice of anticoagulant medication depends on several factors, including the patient's medical history, the presence of comorbidities, and the risk of bleeding.

It is important to monitor patients with gout who are taking anticoagulant therapy closely for signs of bleeding or other side effects. Patients should also be advised to avoid activities that increase the risk of bleeding, such as contact sports or high-impact exercise. In addition, patients should be educated about the signs and symptoms of bleeding and instructed to seek medical attention

REFERENCES:

1. Messerli, F.H., E.D. Frohlich, G.R. Dreslinski, D.H. Suarez and G.G. Aristimuno, 1980. Serum uric acid in essential hypertension: An indication of renal vascular involvement. *Ann. Intern. Med.*, 93: 817-821.
2. Grahame, R. and J.T. Scott, 1970. Clinical survey of 352 patients with gout. *Ann. Rheum. Dis.*, 29: 461-468.
3. Lieber, C.S., D.P. Jones, M.S. Losowsky and C.S. Davidson, 1962. Interrelation of uric acid and ethanol metabolism in man. *J. Clin. Invest.*, 41: 1863-1870. [PubMed](#)
4. Darlington, L.G. and J.T. Scott, 1972. Plasma lipid levels in gout. *Ann. Rheum. Dis.*, 31: 487-489.
5. Feldman, E.B. and S.L. Wallace, 1964. Hypertriglyceridemia in gout. *Circulation*, 29: 508-513.
6. Darlington, L.G., J. Slack and J.T. Scott, 1982. Family study of lipid and purine levels in gout patients. *Ann. Rheum. Dis.*, 41: 253-256.
7. Viozzi, Frank J.; Bluhm, Gilbert B.; and Riddle, Jeanne M. (1972) "Gout and Arterial Thrombosis," *Henry Ford Hospital Medical Journal* : Vol. 20 : No. 3 , 119-124. Available at: <https://scholarlycommons.henryford.com/hfhmedjournal/vol20/iss3/1>
8. Gilbert B. Bluhm, Jeanne M. Riddle, Platelets and vascular disease in gout, *Seminars in Arthritis and Rheumatism*, Volume 2, Issue 4, 1973, Pages 355-366, ISSN 0049-0172, [https://doi.org/10.1016/0049-0172\(73\)90023-1](https://doi.org/10.1016/0049-0172(73)90023-1).
9. D.J.C. Ramsey, S. Cotton, E.S. Lawrence, M.J. Semple, P.F. Worth, A. Petrie, T.W. Stone and L.G. Darlington, 2005. Clotting Factors in Patients with Acute and Chronic Gout. *Journal of Medical Sciences*, 5: 47-



1. **DOI:** 10.3923/jms.2005.47.51
URL: <https://scialert.net/abstract/?doi=jms.2005.47.51>
10. MUSTARD JF, MURPHY EA, OGRYZLO MA, SMYTHE HA. BLOOD COAGULATION AND PLATELET ECONOMY IN SUBJECTS WITH PRIMARY GOUT. *Can Med Assoc J.* 1963 Dec 14;89(24):1207-11. PMID: 14084698; PMCID: PMC1922159.
11. Daisy Vedder^{1,2} · Martijn Gerritsen¹ · Joost C. M. Meijers^{3,4} · Michael T. Nurmohamed^{1,2,5} Coagulation in gout: is there a link with disease activity? *Clinical Rheumatology* (2022) 41:1809–1815
<https://doi.org/10.1007/s10067-022-06047-9pro>
12. Richard J. Johnson, Duk-Hee Kang, Daniel Feig, Salah Kivlighn, John Kanellis, Susumu Watanabe,
13. Katherine R. Tuttle, Bernardo Rodriguez-Iturbe, Jaime Herrera-Acosta, Marilda Mazzali. Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease? (*Hypertension.* 2003;41:1183-1190.)
<http://ahajournals.org> by on February 2, 2023
14. Guo, Y, Zhou, F, Xu, H. Gout and risk of venous thromboembolism: A systematic review and meta-analysis of cohort studies. *Int J Rheum Dis.* 2023; 26: 344- 353. doi:10.1111/1756-185X.14524
15. Kruchinova, S.; Shvartz, V.; Namitokov, A.; Gendugova, M.; Karibova, M.; Kosmacheva, E. Prevalence of Polymorphisms of Genes Responsible for Coagulation System and Folate Metabolism and Their Predictive Value for Thrombosis Development in MINOCA Patients: Immediate and Long-Term Prognoses. *Cardiogenetics* 2023, 13, 47-60.
<https://doi.org/10.3390/cardiogenetics13020006>
16. Coburn BW, Mikuls TR. Treatment Options for Acute Gout. *Fed Pract.* 2016 Jan;33(1):35-40. PMID: 30766136; PMCID: PMC6366613.
17. Michael H. Pillinger, Brian F. Mandell, Therapeutic approaches in the treatment of gout, *Seminars in Arthritis and Rheumatism*, Volume 50, Issue 3, Supplement, 2020, Pages S24-S30, ISSN 0049-0172, <https://doi.org/10.1016/j.semarthrit.2020.04.010>.
18. Lisa K. Stamp, Peter T. Chapman, Gout and its comorbidities: implications for therapy, *Rheumatology*, Volume 52, Issue 1, January 2013, Pages 34–44, <https://doi.org/10.1093/rheumatology/kes211>